William Lyman
Carbondale, ILNPI 1760003321
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 357 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 26.6% of the total.
Across 357 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Corium, LLC$586
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$582
- Axsome Therapeutics, Inc.$487
- Teva Pharmaceuticals USA, Inc.$483
- Vanda Pharmaceuticals Inc.$468
- plus $3K from 20 others
What the payments were for
- Food & beverage$7,50398%
- Education$1522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 102 | $2,034 |
| Corium, LLC | 22 | $586 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $582 |
| Axsome Therapeutics, Inc. | 18 | $487 |
| Teva Pharmaceuticals USA, Inc. | 21 | $483 |
| Vanda Pharmaceuticals Inc. | 14 | $468 |
| Otsuka America Pharmaceutical, Inc. | 21 | $460 |
| Lundbeck LLC | 18 | $337 |
| Alkermes, Inc. | 14 | $282 |
| Johnson & Johnson | 8 | $195 |
| Tris Pharma Inc | 10 | $194 |
| Indivior Inc. | 8 | $171 |
| Idorsia Pharmaceuticals US Inc | 11 | $166 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $155 |
| Almatica Pharma LLC | 6 | $154 |
| Ironshore Pharmaceuticals Inc. | 7 | $144 |
| Noven Therapeutics, LLC | 6 | $118 |
| E.r. Squibb & Sons, L.L.C. | 5 | $113 |
| Neurocrine Biosciences, Inc. | 4 | $103 |
| Supernus Pharmaceuticals, Inc. | 4 | $103 |
| Sunovion Pharmaceuticals Inc. | 7 | $87 |
| Biogen | 3 | $74 |
| Eisai Inc. | 4 | $66 |
| Jazz Pharmaceuticals Inc. | 3 | $64 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Orexo US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 30 | $48,342 |
| Invega SustennaPaliperidone Palmitate | 11 | $36,950 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $27,274 |
| Aripiprazole | 87 | $7,365 |
| QuviviqDaridorexant Hcl | 11 | $5,512 |
| Clozapine | 78 | $3,713 |
| Oxcarbazepine | 56 | $3,376 |
| Ramelteon | 19 | $2,275 |
| Quetiapine Fumarate | 75 | $2,213 |
| Bupropion XlBupropion Hcl | 98 | $2,180 |
| Escitalopram Oxalate | 107 | $1,930 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 44 | $1,809 |
| Trazodone Hcl | 159 | $1,612 |
| Alprazolam | 198 | $1,483 |
| Mirtazapine | 50 | $1,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,034 | $48,34230 claims |
| Johnson & JohnsonInvega Sustenna | $195 | $36,95011 claims |
| Alkermes, Inc.Lybalvi | $282 | $27,27412 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $166 | $5,51211 claims |
| Almatica Pharma LLCSertraline Hcl | $154 | $72460 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Illinoison file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.